EPS for Novartis AG (NVS) Expected At $1.16

January 18, 2018 - By Michael Collier

 EPS for Novartis AG (NVS) Expected At $1.16

Analysts expect Novartis AG (NYSE:NVS) to report $1.16 EPS on January, 24.They anticipate $0.04 EPS change or 3.57 % from last quarter’s $1.12 EPS. NVS’s profit would be $2.73 billion giving it 18.67 P/E if the $1.16 EPS is correct. After having $1.29 EPS previously, Novartis AG’s analysts see -10.08 % EPS growth. The stock decreased 0.31% or $0.27 during the last trading session, reaching $86.61. About 547,260 shares traded. Novartis AG (NYSE:NVS) has risen 7.67% since January 18, 2017 and is uptrending. It has underperformed by 9.03% the S&P500.

Novartis AG (NYSE:NVS) Ratings Coverage

Among 16 analysts covering Novartis Ag (NYSE:NVS), 5 have Buy rating, 4 Sell and 7 Hold. Therefore 31% are positive. Novartis Ag has $110 highest and $7700 lowest target. $93.40’s average target is 7.84% above currents $86.61 stock price. Novartis Ag had 34 analyst reports since July 28, 2015 according to SRatingsIntel. The firm earned “Neutral” rating on Friday, June 16 by J P Morgan Chase Co. The company was downgraded on Tuesday, January 3 by JP Morgan. The stock of Novartis AG (NYSE:NVS) earned “Overweight” rating by Morgan Stanley on Wednesday, July 26. The firm earned “Neutral” rating on Thursday, March 23 by Goldman Sachs. The firm has “Underperform” rating by Morgan Stanley given on Tuesday, April 12. The rating was maintained by Leerink Swann on Monday, October 23 with “Market Perform”. The stock of Novartis AG (NYSE:NVS) has “Market Perform” rating given on Wednesday, March 23 by Leerink Swann. The company was maintained on Tuesday, July 18 by Cowen & Co. The firm earned “Hold” rating on Tuesday, April 5 by Argus Research. The rating was upgraded by Barclays Capital to “Hold” on Friday, June 23.

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company has market cap of $203.98 billion. The companyÂ’s Innovative Medicines segment offers patented prescription medicines to enhance health outcomes for patients and health-care providers. It has a 30.86 P/E ratio. This divisions also franchises ophthalmology, neuroscience, immunology and dermatology, respiratory, cardio-metabolic, and other medicines, as well as cell and gene therapies.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.